News Hub | News Direct

HUSQVARNA® VIKING® Introduces Epic Quilt™ 97

SVP Worldwide

SVP Worldwide, the parent company of HUSQVARNA® VIKING®, a leader in the sewing industry, proudly announced today the launch of its latest innovation, the Epic Quilt™ 97, what quilt dreams are made of. The Epic Quilt™ 97 boasts a spacious workspace perfect for large projects, accommodating even king-sized quilts. With over 12" (310mm) to the right of the needle and a working area height exceeding 5.5" (140mm), it provides ample room for handling bulky materials. A particular standout feature of the Epic Quilt™ 97 is its sewing projection technology, allowing quilters to preview their stitches before sewing. Stitch preview ensures perfect placement every time. The adjustable lines, angles, and grids in sewing mode make aligning stitches effortless, saving valuable time while achieving precision. The Epic Quilt™ 97 also comes equipped with meticulously designed accessories that enhance creativity and ease of use. Included are advanced accessories providing quilters with the tools needed to elevate their craft to new heights including an Extension Table with Adjustable Guide, Rotating Self Healing Cutting Mat (12” x 12”), Rotary Cutting Tool + Replacement Blades, Ruler Set (6” x 12” and 6” x 6” sizes), Free Motion Ruler Foot, Quilt Binder, HUSQVARNA® VIKING® Universal Needles 80/12 5-Pack and the HUSQVARNA® VIKING® Quilting Needles Assorted Sizes 5-Pack. "We are excited to unveil the Epic 97Q, a groundbreaking advancement in our tradition of innovation,” stated Jason Zielke, chief product officer at SVP Worldwide. “Leveraging AI technology, the machine recommends the optimal sewing foot setup for each stitch, and the built-in projection system simplifies the process of creating complex stitches leading to exceptional precision and quality. We added to this machine a suite of the most important accessories that will advance the quilting experience. The Epic 97Q combines our rich heritage with cutting-edge technology, empowering you to create intricate, beautifully executed quilts with unparalleled ease and accuracy." The Epic Quilt 97 is now available online. For more information, please visit our website at www.husqvarnaviking.com. Media Assets About SVP Worldwide SVP Worldwide is the world’s largest consumer sewing machine company, accounting for approximately one out of every three sewing machines sold globally. The company’s iconic brands - SINGER®, VIKING®, PFAFF®, and mySewnet™, have collectively delighted consumers for over 170 years with a distinct heritage and global fanbase. These premium brands and products are regarded as the first-rate choice for a range of consumers from serious sewists to beginners in crafting. SVP Worldwide operates facilities around the globe that support designing, manufacturing, selling, and supplying the world’s most iconic sewing machine brands. Headquartered out of Nashville, TN (USA) with operations internationally, SVP Worldwide boasts regional headquarters, manufacturing facilities, and commercial offices across Europe, South America, Asia, and Australia. Combined, SVP reaches consumers in more than 180 countries on five continents. SVP brands and products are sold online at www.Singer.com and across a network of sewing machine dealers, mass, online, and specialty retailers, distributors, and through the company’s 130+ internally operated retail stores. In 2021, Platinum Equity acquired the controlling stake in SVP-Singer Holdings, Inc., and its wholly owned subsidiaries ("SVP Worldwide"). To learn more, visit www.svpworldwide.com. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com

October 10, 2024 10:00 AM Central Daylight Time

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Equality CA Presents 2024 Community Leadership Award to Greg Sarris

Federated Indians of Graton Rancheria

Equality CA, the nation’s largest statewide LGBTQ+ civil rights organization, presented Tribal Chairman Greg Sarris with their annual Community Leadership Award at their gala in Los Angeles. The award celebrates Chairman Sarris’ longtime service to equal rights, and was presented by California State Treasurer, Fiona Ma. In presenting the award, Ma commented, “I'm thrilled to present honoree Dr. Greg Sarris, whose activism and philanthropic efforts over many years have improved the lives of so many. He has also been incredibly generous in supporting LGBTQ causes and uplifting underrepresented communities.” Chairman Sarris commented, “In Los Angeles this past Saturday, I was presented with the Community Leadership Award from Equality, California. I accepted this award on behalf of and in recognition of my wonderful Tribe, the Federated Indians of Graton Rancheria. Our Tribal Council has generously supported not just Equality California but a host of other organizations and causes in line with our mission of social justice and environmental leadership. This particular honor was special to me. I believe service to others and the larger world is needed now more than ever, and certainly is in line with the beliefs and life ways of our Southern Pomo and Coast Miwok ancestors. Whether university teaching for over 35 years, Tribal leadership for over 30 years and writing several books with the hope of educating others, I’ve lived my best moments in service. Thank you, Tribal Council and all Tribal Citizens of Federated Indians of Graton Rancheria, thank you students and book publishers for enabling me to live my best life.” About the Federated Indians of Graton Rancheria Graton Rancheria is a federally recognized Indian tribe comprised of Coast Miwok and Southern Pomo Indians. Legislation restoring federal recognition to the Federated Indians of Graton Rancheria was signed into law in December 2000. Tribal lands are located in Rohnert Park, Sonoma County, CA. For more information about FIGR, visit www.gratonrancheria.com. Contact Details Landis Communications Inc. Brianne Miller +1 415-766-0887 graton@landispr.com Company Website https://gratonrancheria.com/

October 08, 2024 01:41 PM Pacific Daylight Time

Image

Former USC Student-Athlete L Simpson Launches "Take No L’s" Collection with Shiekh at USC Village

Full Scope PR

Current USC student, former USC football player and fashion entrepreneur L Simpson is rewriting the playbook for student-athletes with the exclusive launch of his highly anticipated streetwear collection, “Take No L’s”, at Shiekh at USC Village on Sept. 26. What began as a middle school project has evolved into a brand that embodies a mindset of relentless determination: no losses, only lessons – whether it’s on the court, field or in life. “Take No L’s” gained significant traction throughout Simpson’s high school basketball career at Sierra Canyon High School (Chatsworth, Calif.), where he captained his team to back-to-back California Open State Championships alongside notable teammates Scottie Pippen Jr., KJ Martin, Cassius Stanley and Christian Koloko. The brand’s momentum continued to increase when he joined USC’s renowned football program. Coached by USC head coach Lincoln Riley alongside former teammates and current NFL players, Caleb Williams, Jordan Addison and Brenden Rice, “Take No L’s” quickly became a regularly worn brand among his teammates and coaches. “I’m thrilled for L,” said USC head coach Lincoln Riley. “It’s always great to watch our players achieve their dreams, both on and off of the field. Whether we’re on campus or around the city, our players and staff love wearing the brand. L is extremely bright and innovate, and I know he is going to be incredibly successful.” “This launch is special,” says Simpson. “I shopped at Shiekh as a kid. Whenever Jordans would drop or when I wanted new athletic gear, I would always ask my parents to take me to Shiekh. It truly does feel like a full- circle moment. We’re not just selling clothes; we’re promoting a mindset of going after your dreams and never accepting defeat. That’s what Take No L’s stands for—no losses, just lessons.” Take No L’s is a bold, confident and unapologetic premium streetwear brand featuring striking graphics and vibrant colors. The collection includes hoodies, cropped sweatshirts, t-shirts, sweatpants and hats, with prices ranging from $90 to $200. With significant attention from L’s influencer network, which boasts a combined reach of over 100 million followers, the brand is already generating buzz on social media. Join Simpson on Sept. 26 from 3 p.m. to 6 p.m. PT at Shiekh in USC Village for the official launch of the “Take No L’s” collection. Experience firsthand why “Take No L’s” is setting a new standard in streetwear. The event will include special appearances, exclusive products and live entertainment featuring stars like Storm Reid, Brenden Rice, Riri Simpson, Jazz Hill, Temi Ojoro, Tade Ojoro, Ceyair Wright, Amber Jasmine, Lboogz, and Saint Thomas. Don't miss this exciting celebration of fashion and culture! About L Simpson: L Simpson, current USC student and former student-athlete, is the founder of the “Take No L’s” brand. Inspired by sports, culture and the journey of perseverance, Simpson created “Take No L’s” to encourage people to live fearlessly and embrace a lifestyle without losses. Simpson’s collection combines bold design, high-quality fabrics and empowering messaging to create a distinctive streetwear line that resonates with today’s generation. L has previously hosted his own talk show on SLAM and recently co-hosted the “Almost Pro” podcast with former Heisman Trophy winner Caleb Williams. Simpson is currently pursuing a degree in communication from the USC Annenberg School of Communication and Journalism, and he will graduate in the spring of 2025. For more info on the brand, visit takenolsstore.com and follow Simpson on Instagram at @lboogz. About Shiekh Shoes: Style Elevated, Sneakers Celebrated. Shiekh offers a curated collection of footwear, apparel, and accessories. Explore top brands like Nike, Adidas, and Jordan at Shiekh. Shiekh stores can be found at premium locations in multiple states. For more information follow @Shiekh on Instagram and visit Shiekh.com Media Contact: Pia Malihi | Full Scope PR pia@fullscopepr.com # # # Contact Details Pia Malihi pia@fullscopepr.com Company Website https://takenolsstore.com/

September 26, 2024 01:12 AM Eastern Daylight Time

Image

Little Spoon Becomes The First and Only Baby Food Maker In the U.S. To Publicly Set EU-Aligned Safety Standards and Share Test Results for Heavy Metals, Pesticides + Plasticizers

Little Spoon

In a groundbreaking move for the baby food industry, Little Spoon, the largest online baby and kids food company in the United States, today becomes the first and only brand in the country to unveil its testing standards and results for heavy metals, pesticides and plasticizers, making a commitment to never sell any product that falls short of its strict limits. The launch of this significant transparency initiative comes in response to the ongoing national discussion about baby food safety, the urgent need for stricter industry standards, and staggering statistics from a recently commissioned study of 2,000 American parents with children under 2 years old. As national conversations on baby food safety rapidly gain steam, it has become impossible to ignore the concerning headlines on toxic levels of heavy metals, grocery store brand misinformation and deteriorating consumer trust. Little Spoon partnered with Talker Research to conduct a survey of 2,000 American Parents to pulse check the needs and standards of American parents, and the results uncovered astonishing levels of mistrust and concern around industry safety, federal regulations, and overarching brand commitment. In fact, 95% of parents agree that baby food brands should be doing more to address baby food safety concerns— and only 9% report a ‘high degree’ of trust in baby food companies. “Quality nutrition and confidence in the products that fuel your family are rights, not privileges.” said co-founder and CEO, Ben Lewis. “We view this as a fundamental responsibility for our industry and a key reason why Little Spoon exists in the first place. The standards for children’s food in the U.S. are maddeningly low. Parents deserve better, and we are doing our part to finally deliver what they deserve.” Established to bring change to a century old industry, Little Spoon is once again raising the bar in the category by testing and sharing results for every batch of baby food for 500+ contaminants including heavy metals, pesticides, glyphosate and plasticizers. With no current federal regulations set for limiting the levels of chemical contaminants in baby food in the U.S., Little Spoon has aligned its testing standards for heavy metals with the European Union (EU), a long-standing, trusted standard for safety and excellence in the baby space. Consumers can see exact testing limits for each contaminant through a dashboard viewable for every Babyblend product on the brand’s website and can confidently purchase products knowing Little Spoon will not sell any products that do not meet these standards. “This generation is plagued by concern regarding baby food safety — and for good reason.” said co-founder and Chief Product Officer of Little Spoon, Angela Vranich. “We have always crafted our products with the utmost care, using certified organic ingredients and differentiated processing. We knew we could meet the rigorous EU testing limits for heavy metals in our baby food, and it quickly became our obsession to provide the level of transparency parents truly deserve.” To draw further attention to this crucial issue for Little Spoon consumers and parents nationwide, the ‘Little Spoon, Big Change’ initiative will be driven by a comprehensive 360-degree marketing campaign launching today. Designed to meet parents’ growing demands for transparency and baby food safety, the campaign will feature media partners, celebrities, tastemakers, and experts including an expanded advisory panel which now features world-class experts in public policy and academics specializing in heavy metals. As a topic often fraught with fear mongering tactics, Little Spoon is leveraging experts, educators and a new AI-powered chatbot on their site to provide education for parents and support the wide-ranging questions that come with baby food safety. "We won't see large-scale changes until companies like Little Spoon take action," said Dr. Bruce Lanphear, an advisor to Little Spoon who studies childhood exposure to toxic chemicals. "Companies don't need to wait for regulations—they can lead the charge.” Test results for every Little Spoon Babyblend, alongside detailed ingredient sourcing information are now available on LittleSpoon.com, with plans to roll out additional transparency measures for their robust portfolio of products in the coming months. For complete details on the ‘Little Spoon, Big Change’ initiative including Little Spoon’s testing process, regulation limits, test results, and overall commitment to baby food safety, please visit LittleSpoon.com and follow @littlespoon on Instagram. Little Spoon is the leading direct-to-consumer kid’s food brand on a mission to make parents' lives easier, and kids healthier through high-quality, accessible feeding solutions from baby’s first bites through the big kid years. Little Spoon is conveniently delivering the future of kid’s food right to parent’s doorsteps with integrated products that age with your child through a portfolio of freshly-made baby food, early finger foods, toddler + big kid meals, and snacks that meet the modern standard on quality, nutrition and value. Since launch, the company has delivered more than 50 million meals, helping to simplify the lives of hundreds of thousands of parents across the U.S.. With more than 90% of new parents identifying as millennials, Little Spoon is here to disrupt the +$100B children's health and wellness market, offering modern solutions, trusted resources, and new ways to connect with a network of advisors and parents just like you. Learn more at LittleSpoon.com, or find Little Spoon on Instagram at @LittleSpoon. Contact Details Powers PR Alex Turk +1 516-306-2373 alext@powers-pr.com

September 25, 2024 09:03 AM Eastern Daylight Time

Image

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Mothers' Milk Bank California Welcomes New Board Members

The Mothers' Milk Bank

Mothers' Milk Bank California (MMBCA) today announced the appointment of three community leaders to its Board of Directors. These new members bring a diverse range of expertise and a shared passion for supporting vulnerable infants, further bolstering MMBCA's mission to provide life-saving donor human milk to those in need. Their leadership will play a critical role in advancing our efforts to ensure every baby has access to the vital nutrition they require. "Our new board members bring invaluable experience and a deep commitment to our mission. Their diverse backgrounds and shared dedication to supporting vulnerable infants will strengthen our efforts to provide life-saving donor human milk to those who need it most. We are excited to welcome them to the MMBCA family as we continue to work towards ensuring every baby has access to the vital nutrition they need,” Katie Anderson, Board Chair, Mothers' Milk Bank California Kristin is Senior Director of Development and Communications at the National Fragile X Foundation, a patient advocacy organization that supports families living with Fragile X, a group of conditions associated with alterations of the FMR1 gene on the X chromosome. She has over 20 years of experience in fundraising and non-profit management, event planning, and board and volunteer development. She earned a BA in Economics from UC Berkeley and a MA in Public Administration from the Middlebury Institute of International Studies. Peter Bailinson is a SF-based entrepreneur. He's worked at a variety of social impact organizations over his career, most recently as Director of Strategy and Business Operations at Atticus, a public interest law firm. Previously he was an Engagement Manager at McKinsey & Company and managed their global LGBTQ+ initiatives. He graduated with an MBA from Stanford University’s Graduate School of Business and a BA from Columbia University. He's passionate about making it easier for Americans to start and grow families and has conducted extensive research on human milk sharing. Lauren Morgan is a nonprofit professional currently in Program Operations at the Energy Foundation. She began her involvement with Mothers’ Milk Bank California as a donor, giving hundreds of ounces of breast milk. Passionate about scaling nonprofits, Lauren previously led fundraising at GRID Alternatives and managed youth programs at Planet Granite. She also served in AmeriCorps, developing a community garden program in Boston Public Schools. Lauren holds degrees in Religious Studies and Environmental Studies from Brown University and serves on the board of Weekend Adventures. For more information about Mothers' Milk Bank California and our new board members, please visit MothersMilk.org or contact Jennifer Benito at jbenito@MothersMilk.org About Mothers' Milk Bank California Founded 50 years ago, Mothers’ Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers’ Milk Bank California supports families and advances neonatal care. More information at MothersMilk.org ### Founded 50 years ago, Mothers' Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers' Milk Bank California supports families and advances neonatal care. Contact Details Jennifer Benito-Kowalski +1 408-831-7276 jbenito@mothersmilk.org Company Website https://camilkbank.org/

September 18, 2024 06:00 AM Eastern Daylight Time

Flash Transforms Parking at Denver International Airport

Flash

Flash, the leading end-to-end parking technology platform, announced today it has completed an overhaul of public and employee parking at Denver International Airport (DEN) through a contract the City and County of Denver awarded in August 2024. In just 22 days, Flash deployed its platform across the airport’s nine public and employee parking garages and lots, bringing a state-of-the-art parking experience to DEN’s 40,000 employees and the 77.8 million passengers they serve annually. "Flash’s commitment to DEN has been tremendous and we look forward to a bright future that provides innovative solutions to improve the customer experience," said Mark Nagel, Senior Vice President of Parking and Commercial Transportation, Denver International Airport. In its first few weeks of deployment, DEN reports improved traffic flow and reduced wait times for vehicles entering and exiting the airport’s parking facilities. DEN’s deployment of Flash’s platform spans 144 lanes and features 137 kiosks, 97 license plate recognition (LPR) lanes, and 49 automatic vehicle identification (AVI) lanes. With the new AVI lanes, employees can enter and exit automatically in seconds via vehicle-mounted passes that require no interaction with their phones or kiosks. “DEN is the sixth busiest airport in the world and sees millions of parking transactions each year, requiring the highest service level,” said Flash CEO Dan Sharplin. “Our technology breadth and industry-leading scale, plus our maniacal focus on the driver experience, made us confident we could support DEN’s traffic volumes and service levels while getting passengers and employees through parking transactions quickly, and it’s hugely gratifying to see it live.” DEN also benefits from the Flash platform’s design as an enhanced cloud-based parking solution. In the event of an internet, payment processor, network or cloud disruption, the platform maintains continuous operations and critical payment processing capabilities so the airport’s parking facilities stay up and running. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived.. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 12, 2024 09:00 AM Central Daylight Time